Compare KE & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KE | DAWN |
|---|---|---|
| Founded | 1961 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.4M | 624.8M |
| IPO Year | N/A | 2021 |
| Metric | KE | DAWN |
|---|---|---|
| Price | $28.98 | $9.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $28.00 | $26.56 |
| AVG Volume (30 Days) | 155.4K | ★ 3.0M |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.88 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $1,478,074,000.00 | $133,672,000.00 |
| Revenue This Year | N/A | $15.51 |
| Revenue Next Year | $4.71 | $49.99 |
| P/E Ratio | $30.29 | ★ N/A |
| Revenue Growth | N/A | ★ 31.11 |
| 52 Week Low | $12.41 | $5.64 |
| 52 Week High | $33.19 | $13.53 |
| Indicator | KE | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 59.11 |
| Support Level | $28.36 | $8.13 |
| Resistance Level | $31.45 | $10.47 |
| Average True Range (ATR) | 1.01 | 0.62 |
| MACD | -0.13 | 0.11 |
| Stochastic Oscillator | 26.49 | 66.15 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.